EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Extracellular Vesicles in Alzheimer’s Disease: Mechanisms, Biomarkers, and Therapeutic Engineering

Lian Wang iD, Liwei Mao iD, Xuemei Zong iD

International Journal of Molecular Sciences · 29.04.2026 · 27 (9) · 3974

DOI: 10.3390/ijms27093974 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 29.04.2026. Verfasst von Lian Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Institute for Cerebrovascular and Neuroregeneration Research (ICNR), Louisiana State University Health Sciences Center, 1501…. Hauptthemen laut MEDLINE: Alzheimer Disease, Extracellular Vesicles, Biomarkers. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 183 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: American Heart Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular vesicles (EVs) are nanoscale membrane-bound particles that mediate intercellular communication by transferring proteins, nucleic acids, lipids, and metabolites. Increasing evidence implicates EVs in Alzheimer’s disease (AD) pathogenesis through the propagation of amyloid-β, tau, and neuroinflammatory signals across neural and glial networks. In parallel, EVs isolated from biofluids have emerged as promising sources of disease-associated biomarkers and potential therapeutic carriers. This review aims to synthesize current evidence on EV-mediated mechanisms in AD, evaluate the diagnostic value of EV-associated biomarkers, and discuss emerging EV-based and bioengineered therapeutic strategies. We summarize how EVs derived from neurons, astrocytes, microglia, and peripheral cells contribute to amyloid-β and tau spread, neuroinflammation, synaptic dysfunction, and metabolic stress in AD. Disease-associated alterations in EV cargo from blood, cerebrospinal fluid, and urine are critically assessed for biomarker applications. We further highlight advances in EV bioengineering, including cargo loading, surface modification, targeting strategies, and modulation of EV biogenesis. Finally, key translational challenges—such as EV heterogeneity, biodistribution, immune clearance, and standardization—are discussed to define future directions for leveraging EVs as diagnostic and therapeutic platforms in AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseExtracellular VesiclesBiomarkersHumansAnimalsBioengineeringAmyloid beta-Peptides

Stichwörter der Autor:innen

Alzheimer’s diseaseBioengineeringMesenchymal stem cellsNoncoding RNAextracellular vesicles

Substanzen

BiomarkersAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Neurology, Institute for Cerebrovascular and Neuroregeneration Research (ICNR), Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71103, USA.
  • Department of Neurology, Medical College of Georgia, Augusta University, 1120 15th Street, Augusta, GA 30912, USA.

ORCID-Profile: Lian Wang, Liwei Mao, Xuemei Zong

Förderung

  • American Heart Association

Zitieren

APA

Wang, L., Mao, L., & Zong, X. (2026). Extracellular Vesicles in Alzheimer’s Disease: Mechanisms, Biomarkers, and Therapeutic Engineering. International Journal of Molecular Sciences, 27(9), 3974. https://doi.org/10.3390/ijms27093974

Vancouver

Wang L, Mao L, Zong X. Extracellular Vesicles in Alzheimer’s Disease: Mechanisms, Biomarkers, and Therapeutic Engineering. International Journal of Molecular Sciences. 2026;27(9):3974. doi:10.3390/ijms27093974

BibTeX
@article{Wang2026,
  author = {Wang, Lian and Mao, Liwei and Zong, Xuemei},
  title = {Extracellular Vesicles in Alzheimer’s Disease: Mechanisms, Biomarkers, and Therapeutic Engineering},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {9},
  pages = {3974},
  doi = {10.3390/ijms27093974}
}
Kostenlos starten →